The collaboration combines Bend Research’s advanced drug formulation capabilities and Quotient Clinical’s clinical-trial design service, RapidFACT (Rapid Formulation development And Clinical Testing).
RapidFACT represents a new paradigm for drug product optimisation. It exploits Quotient’s integrated formulation development, drug product manufacture, and clinical-testing platform, Quotient Clinical said.
The result is a clinical-trial program that will allow clients to screen and select optimised formulations rapidly during human testing.
Bend Research president and CEO Rod Ray said that the versatility of designing and implementing clinical trials using RapidFACT provides the clients with a game-changing advantage in advancing Quotient’s compounds.
Quotient Clinical managing director Mark Egerton said that access to Bend Research’s formulation expertise through this collaboration will provide the customers with reliable, rapid and efficient drug formulation platforms.
Quotient Clinical is a business unit of Quotient Bioresearch.